tiprankstipranks
Trending News
More News >
Santen Pharmaceutical Co Ltd (SNPHY)
OTHER OTC:SNPHY
Advertisement

Santen Pharmaceutical Co (SNPHY) AI Stock Analysis

Compare
6 Followers

Top Page

SNPHY

Santen Pharmaceutical Co

(OTC:SNPHY)

Select Model
Select Model
Select Model
Neutral 67 (OpenAI - 4o)
Rating:67Neutral
Price Target:
$11.50
▲(15.12% Upside)
Santen Pharmaceutical Co's overall stock score reflects its strong financial performance and reasonable valuation. The company's robust cash flow and low leverage are significant strengths. However, the technical analysis suggests caution due to short-term bearish trends. The absence of earnings call data and corporate events limits additional insights.

Santen Pharmaceutical Co (SNPHY) vs. SPDR S&P 500 ETF (SPY)

Santen Pharmaceutical Co Business Overview & Revenue Model

Company DescriptionSanten Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
How the Company Makes MoneySanten Pharmaceutical generates revenue primarily through the sale of its ophthalmic products, which include prescription drugs, surgical devices, and consumer health products. The company's key revenue streams come from its portfolio of established medications, as well as new products launched in various markets. Additionally, Santen engages in strategic partnerships and collaborations with other pharmaceutical companies and institutions to co-develop new therapies and expand its market reach. These partnerships often involve licensing agreements and joint ventures that contribute to revenue through upfront payments, milestone payments, and royalties on sales. Furthermore, Santen invests in research and development to innovate and expand its product offerings, which helps drive long-term growth and profitability.

Santen Pharmaceutical Co Financial Statement Overview

Summary
Santen Pharmaceutical Co demonstrates strong financial health, characterized by consistent revenue growth, improving profitability margins, and solid cash flow management. The balance sheet reflects stability, although there is room for more efficient capital deployment. The company's financial trajectory is positive, with potential for continued growth and profitability.
Income Statement
75
Positive
Santen Pharmaceutical Co has shown robust revenue growth with a significant increase from the previous year, indicating strong market performance. Gross and net profit margins are healthy, reflecting efficient cost management and profitability. The recovery in EBIT and EBITDA margins from the previous year's negative EBIT further highlights operational improvements.
Balance Sheet
80
Positive
The company's balance sheet is strong, with a solid equity base and a favorable debt-to-equity ratio, indicating financial stability. The equity ratio is healthy, demonstrating a robust capital structure. However, the high amount of cash and equivalents suggests potential underutilization of resources.
Cash Flow
70
Positive
Cash flow performance is excellent, with substantial free cash flow growth and strong operating cash flow relative to net income. The company has effectively managed capital expenditures, enhancing its cash flow stability and flexibility.
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue293.97B300.00B301.96B279.04B266.26B249.60B
Gross Profit165.58B171.03B178.71B166.09B156.59B151.38B
EBITDA61.44B59.01B50.72B12.95B52.93B70.28B
Net Income31.50B36.26B26.64B-14.95B27.22B6.83B
Balance Sheet
Total Assets408.12B409.28B435.70B421.18B459.98B402.35B
Cash, Cash Equivalents and Short-Term Investments84.58B93.99B94.96B58.68B84.31B63.41B
Total Debt0.0034.23B35.16B36.21B32.93B10.15B
Total Liabilities127.91B124.10B130.33B127.88B123.13B95.30B
Stockholders Equity281.26B286.24B306.06B293.98B337.49B307.58B
Cash Flow
Free Cash Flow48.57B54.27B61.96B12.56B10.20B15.00B
Operating Cash Flow56.51B60.93B72.65B37.15B46.04B38.81B
Investing Cash Flow-9.40B-8.22B-6.14B-26.78B-35.17B-53.35B
Financing Cash Flow-49.71B-53.31B-34.03B-37.22B5.56B-16.68B

Santen Pharmaceutical Co Technical Analysis

Technical Analysis Sentiment
Negative
Last Price9.99
Price Trends
50DMA
10.72
Negative
100DMA
11.04
Negative
200DMA
10.42
Negative
Market Momentum
MACD
-0.26
Positive
RSI
30.28
Neutral
STOCH
3.86
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNPHY, the sentiment is Negative. The current price of 9.99 is below the 20-day moving average (MA) of 10.66, below the 50-day MA of 10.72, and below the 200-day MA of 10.42, indicating a bearish trend. The MACD of -0.26 indicates Positive momentum. The RSI at 30.28 is Neutral, neither overbought nor oversold. The STOCH value of 3.86 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNPHY.

Santen Pharmaceutical Co Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
78
Outperform
$88.22B20.1523.04%3.75%3.46%-13.29%
77
Outperform
$261.54B31.2319.76%1.85%15.08%29.15%
76
Outperform
$122.73B12.448.39%4.37%-9.32%120.62%
67
Neutral
$3.45B16.4910.89%2.12%-3.81%22.00%
67
Neutral
$8.51B20.335.41%1.46%10.05%98.22%
66
Neutral
$88.32B17.5129.31%5.68%2.57%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SNPHY
Santen Pharmaceutical Co
9.99
-2.03
-16.89%
AZN
AstraZeneca
84.69
8.84
11.65%
BMY
Bristol-Myers Squibb
43.63
-6.02
-12.12%
GSK
GlaxoSmithKline
43.91
7.39
20.24%
GRFS
Grifols SA
9.65
1.19
14.07%
SNY
Sanofi
50.62
-1.38
-2.65%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 07, 2025